BeiGene Raises $97 Million to Develop Cancer Drug Portfolio

BeiGene, a Beijing biopharma focused on developing novel targeted and immuno-oncology cancer therapies, has completed a $97 million fundraising. Six months ago, BeiGene announced a $75 million Series A financing. BeiGene currently has three small molecule inhibitors in Phase I trials and expects to start a trial of a novel PD-1 monoclonal antibody before the end of 2015. More details.... Share this with colleagues: // //